These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11576767)

  • 41. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes.
    Dubey V; Mishra D; Dutta T; Nahar M; Saraf DK; Jain NK
    J Control Release; 2007 Nov; 123(2):148-54. PubMed ID: 17884226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
    Padamwar MN; Pokharkar VB
    Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus.
    Bendas ER; Abdullah H; El-Komy MH; Kassem MA
    Int J Pharm; 2013 Dec; 458(2):287-95. PubMed ID: 24184035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.
    Doppalapudi S; Jain A; Chopra DK; Khan W
    Eur J Pharm Sci; 2017 Jan; 96():515-529. PubMed ID: 27777066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel vesicular transdermal delivery of nifedipine - preparation, characterization and in vitro/in-vivo evaluation.
    Yasam VR; Jakki SL; Natarajan J; Venkatachalam S; Kuppusamy G; Sood S; Jain K
    Drug Deliv; 2016; 23(2):619-30. PubMed ID: 25005581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery.
    El-Menshawe SF; Hussein AK
    Pharm Dev Technol; 2013; 18(4):779-86. PubMed ID: 21913880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elastic liposome-based gel for topical delivery of 5-fluorouracil: in vitro and in vivo investigation.
    Hussain A; Samad A; Ramzan M; Ahsan MN; Ur Rehman Z; Ahmad FJ
    Drug Deliv; 2016 May; 23(4):1115-29. PubMed ID: 25379805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced Permeation of Methotrexate via Loading into Ultra-permeable Niosomal Vesicles: Fabrication, Statistical Optimization, Ex Vivo Studies, and In Vivo Skin Deposition and Tolerability.
    Al-Mahallawi AM; Fares AR; Abd-Elsalam WH
    AAPS PharmSciTech; 2019 Apr; 20(5):171. PubMed ID: 31004239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimization of methotrexate loaded niosomes by Box-Behnken design: an understanding of solvent effect and formulation variability.
    Zidan AS; Mokhtar Ibrahim M; Megrab NAE
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1450-1459. PubMed ID: 28420295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation.
    Kumar R; Singh B; Bakshi G; Katare OP
    Pharm Dev Technol; 2007; 12(6):591-601. PubMed ID: 18161632
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes.
    Raza K; Katare OP; Setia A; Bhatia A; Singh B
    J Microencapsul; 2013; 30(3):225-36. PubMed ID: 23088318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of dithranol and butantrone in short contact therapy of psoriasis.
    Göransson A
    Acta Derm Venereol; 1987; 67(2):149-53. PubMed ID: 2438880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and characterization of dutasteride bearing liposomal systems for topical use.
    Sharma P; Jain D; Maithani M; Mishra SK; Khare P; Jain V; Singh R
    Curr Drug Discov Technol; 2011 Jun; 8(2):136-45. PubMed ID: 21513483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT.
    Farkas A; Kemény L; Szöny BJ; Bata-Csörgö Z; Pivarcsi A; Kiss M; Széll M; Koreck A; Dobozy A
    Inflamm Res; 2001 Jan; 50(1):44-9. PubMed ID: 11235021
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Encapsulation and stability of clofazimine liposomes.
    Patel VB; Misra AN
    J Microencapsul; 1999; 16(3):357-67. PubMed ID: 10340220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery.
    Gupta M; Vaidya B; Mishra N; Vyas SP
    Artif Cells Blood Substit Immobil Biotechnol; 2011 Dec; 39(6):376-84. PubMed ID: 21951195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment.
    Tripathi PK; Gorain B; Choudhury H; Srivastava A; Kesharwani P
    Heliyon; 2019 Mar; 5(3):e01343. PubMed ID: 30957038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative study of dithranol cream, 0.25% and 0.1%, and dithranol ointment 0.25% in the treatment of psoriasis.
    Fredriksson T
    Pharmatherapeutica; 1983; 3(7):496-8. PubMed ID: 6366807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new approach for the evaluation of niosomes as effective transdermal drug delivery systems.
    Muzzalupo R; Tavano L; Cassano R; Trombino S; Ferrarelli T; Picci N
    Eur J Pharm Biopharm; 2011 Sep; 79(1):28-35. PubMed ID: 21303691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of formulation compositions on niosomal preparations.
    Chaw CS; Kim KY
    Pharm Dev Technol; 2013; 18(3):667-72. PubMed ID: 22468904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.